- Biovian and 3P Biopharmaceuticals have combined to form a new pan-European leader in biologics Contract Development and Manufacturing Organisations (CDMOs), named 3PBIOVIAN.
- The combined group will offer end-to-end development and manufacturing services for all protein expression systems and viral vectors.
- The group aims to spearhead the development of drugs tackling patients’ unmet clinical needs.
Biovian and 3P Biopharmaceuticals, biologics Contract Development and Manufacturing Organisations (CDMOs), announced their combination to establish a new pan-European leader in their field. This strategic move was backed by their common shareholder, Keensight Capital.
The newly formed group, named 3PBIOVIAN, will offer unparalleled end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for Drug Substance and Drug Product, from preclinical to clinical development and commercial phases.
Leveraging a joint 40-year track record, expertise, capabilities, and financial strength, the Group will position itself as a leading pan-European independent biologics CDMO. It aims to spearhead the development of drugs tackling patients’ unmet clinical needs.
Through this combination, the Group will become one of the main independent European bio-CDMOs, with gross sales above €75m. With over 500 professionals and operating across manufacturing facilities of 15,800 square meters, the group is now ideally positioned to effectively address the growing demands of the market.
3PBIOVIAN will continue to be led by its team of seasoned professionals in the biologics industry, driving its growth ambitions going forward. Dámaso Molero Sánchez (former 3P CEO) will serve as Group CEO supported by Deputy CEO Antti Nieminen (former Biovian CEO), Heidi Suuronen as CFO and Elena Erroba as CCO (Chief Commercial Officer).
Overview of outsourcing trends 
